FIELD: pharmaceutics.
SUBSTANCE: invention relates to indole compounds of the formula (I), in which the values of A, L, T, R3-R5 are disclosed in the claims, and its pharmaceutically acceptable salts. The compounds can be used as CRTH2 inhibitor. The invention also relates to the use of compounds of the formula (I) for the treatment of a disease related to CRTH2 receptor, for example, asthma or allergic rhinitis.
EFFECT: obtaining compounds for the treatment of diseases related to CRTH2 receptor.
14 cl, 1 tbl, 82 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF DIARYLTHIOHYDANTOIN COMPOUND AS AN ANDROGEN RECEPTOR ANTAGONIST | 2018 |
|
RU2804108C9 |
FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
ERBB/BTK INHIBITORS | 2019 |
|
RU2764069C1 |
PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
CELL NECROSIS INHIBITOR, METHOD FOR ITS PRODUCTION AND APPLICATION | 2019 |
|
RU2793918C2 |
HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
OXOPICOLINAMIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2017 |
|
RU2742771C2 |
Authors
Dates
2021-09-29—Published
2017-07-21—Filed